Last reviewed · How we verify
Glycopyrronium bromide 12.5ug
At a glance
| Generic name | Glycopyrronium bromide 12.5ug |
|---|---|
| Also known as | NVA237 |
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (PHASE2)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycopyrronium bromide 12.5ug CI brief — competitive landscape report
- Glycopyrronium bromide 12.5ug updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI